RA patients face enrolled in Medicare plan face significant cost exposure on specialty drugs

RA patients face enrolled in Medicare plan face significant cost exposure on specialty drugs

RA patients face enrolled in Medicare plan face significant cost exposure on specialty drugs

After a sharp drop in out-of-pocket costs between 2010 and 2011, Medicare patients who use specialty biologic medications for rheumatoid arthritis have seen higher out-of-pocket spending for those same drugs because of gradual price increases, a new study in the Journal of the American Medical Association Open finds.